Detection of in vivo enzyme activities with CEST MRI

使用 CEST MRI 检测体内酶活性

基本信息

  • 批准号:
    8353415
  • 负责人:
  • 金额:
    $ 53.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Enzyme activities are important biomarkers for cancer diagnoses and assessing chemotherapies. We have developed MRI contrast agents that are detected via Chemical Exchange Saturation Transfer (CEST) and that are responsive to enzyme activity. We have also developed CEST MRI methods that can detect these agents within in vivo tumor tissues in mouse models of human cancers. Importantly, we can selectively detect an enzyme-responsive agent and an unresponsive "control" agent during the same study in the same tissue location, which improves our evaluation of enzyme activity within the mouse model. Just as multiple fluorophores have revolutionized the evaluation of enzyme activities during in vitro and ex vivo studies, CEST agents and CEST MRI has potential to revolutionize the evaluation of enzyme activities in vivo. We propose to build on our recent research successes by linking enzyme-responsive and control agents to create a dimeric agent, by comparing paramagnetic and diamagnetic CEST agents, and by optimizing the saturation period of the CEST MRI acquisition protocol in order to improve the detection sensitivity of CEST MRI. We also propose to develop enzyme-responsive CEST agents that semi-quantitatively detect the activities of urokinase Plasminogen Activator (uPA) in mouse models of pancreatic cancer, Prostate Specific Membrane Antigen (PSMA) in mouse models of prostate cancer, and transglutaminase (TG2) in mouse models of breast cancer. We propose to use these CEST agents and our in vivo CEST MRI methodology to investigate three biomedical aims: A) to predict the effect of chemotherapies before they are administered to mouse models; B) to evaluate early response to chemotherapies; C) to investigate our hypothesis that enzyme activity is a more accurate biomarker than enzyme expression for predicting and evaluating therapeutic effects. Together, these studies address our overarching goal of eventually using CEST agents and CEST MRI to tailor the choice of chemotherapy and treatment regimen for each individual patient, in order to support the paradigm of personalized medicine. PUBLIC HEALTH RELEVANCE: We propose to continue to develop CEST agents and CEST MRI methods that detect enzyme activities within in vivo mouse models of cancer. We propose to use our CEST agents and CEST MRI methods to evaluate chemotherapies and to assess whether enzyme activity is a better biomarker than enzyme expression.
描述(由申请人提供):酶活性是癌症诊断和评估化疗的重要生物标志物。我们已经开发了通过化学交换饱和转移(CEST)检测的MRI造影剂,并且对酶活性有反应。我们还开发了CEST MRI方法,可以在人类癌症小鼠模型的体内肿瘤组织中检测这些药物。重要的是,我们可以在相同的研究中在相同的组织位置选择性地检测酶反应剂和无反应的“对照”剂,这改善了我们对小鼠模型中酶活性的评估。正如多种荧光团在体外和离体研究中彻底改变了酶活性的评价一样,CEST试剂和CEST MRI有可能彻底改变体内酶活性的评价。我们建议建立在我们最近的研究成功,通过连接酶响应和控制剂,以创建一个二聚体的代理,通过比较顺磁性和抗磁性CEST代理,并通过优化饱和期的CEST MRI采集协议,以提高CEST MRI的检测灵敏度。我们还建议开发酶响应CEST试剂,半定量检测胰腺癌小鼠模型中尿激酶纤溶酶原激活物(uPA)、前列腺癌小鼠模型中前列腺特异性膜抗原(PSMA)和乳腺癌小鼠模型中转氨酶(TG 2)的活性。我们建议使用这些CEST试剂和我们的体内CEST MRI方法来研究三个生物医学目的:A)在给予小鼠模型之前预测化疗的效果; B)评估对化疗的早期反应; C)研究我们的假设,即酶活性是比酶表达更准确的生物标志物,用于预测和评估治疗效果。总之,这些研究解决了我们的总体目标,即最终使用CEST药物和CEST MRI为每位患者量身定制化疗和治疗方案的选择,以支持个性化医学的范式。 公共卫生关系:我们建议继续开发CEST试剂和CEST MRI方法,以检测体内小鼠癌症模型中的酶活性。我们建议使用我们的CEST试剂和CEST MRI方法来评估化疗,并评估酶活性是否是比酶表达更好的生物标志物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark David Pagel其他文献

Mark David Pagel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark David Pagel', 18)}}的其他基金

Exploiting Melanin Synthesis to Improve Tumor Detection with Multispectral Optoacoustic Tomography and Optical Guided Surgery
利用多光谱光声断层扫描和光引导手术利用黑色素合成来改善肿瘤检测
  • 批准号:
    9978211
  • 财政年份:
    2020
  • 资助金额:
    $ 53.28万
  • 项目类别:
Exploiting Melanin Synthesis to Improve Tumor Detection with Multispectral Optoacoustic Tomography and Optical Guided Surgery
利用多光谱光声断层扫描和光引导手术利用黑色素合成来改善肿瘤检测
  • 批准号:
    10152589
  • 财政年份:
    2020
  • 资助金额:
    $ 53.28万
  • 项目类别:
Measuring Tumor Acidosis with PET/MRI Contrast Agents
使用 PET/MRI 造影剂测量肿瘤酸中毒
  • 批准号:
    9750458
  • 财政年份:
    2019
  • 资助金额:
    $ 53.28万
  • 项目类别:
Early phase clinical trial for imaging tumor acidosis in breast cancer patients using acidoCEST MRI
使用 AcidoCEST MRI 对乳腺癌患者肿瘤酸中毒进行成像的早期临床试验
  • 批准号:
    8948796
  • 财政年份:
    2015
  • 资助金额:
    $ 53.28万
  • 项目类别:
Detection of in vivo enzyme activities with CEST MRI
使用 CEST MRI 检测体内酶活性
  • 批准号:
    8495297
  • 财政年份:
    2012
  • 资助金额:
    $ 53.28万
  • 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
  • 批准号:
    8446309
  • 财政年份:
    2012
  • 资助金额:
    $ 53.28万
  • 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
  • 批准号:
    8286741
  • 财政年份:
    2012
  • 资助金额:
    $ 53.28万
  • 项目类别:
Detection of in vivo enzyme activities with CEST MRI
使用 CEST MRI 检测体内酶活性
  • 批准号:
    8852091
  • 财政年份:
    2012
  • 资助金额:
    $ 53.28万
  • 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
  • 批准号:
    8817152
  • 财政年份:
    2012
  • 资助金额:
    $ 53.28万
  • 项目类别:
Detection of in vivo protease activities using PARACEST MRI contrast agents
使用 PARACEST MRI 造影剂检测体内蛋白酶活性
  • 批准号:
    7451742
  • 财政年份:
    2008
  • 资助金额:
    $ 53.28万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 53.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了